Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the sale, the insider directly owned 1,176,506 shares of the company’s stock, valued at $7,129,626.36. This represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.23, for a total transaction of $103,835.41.
• On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $5.99, for a total transaction of $99,835.33.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $5.89 on Thursday. The company has a market cap of $1.02 billion, a price-to-earnings ratio of 98.17 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a 52 week low of $4.30 and a 52 week high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The firm has a 50 day moving average of $6.06 and a 200-day moving average of $6.60.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The company had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Hedge Funds Weigh In On Xeris Biopharma

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after purchasing an additional 135,815 shares in the last quarter. State Street Corp lifted its holdings in shares of Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Xeris Biopharma by 6.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on XERS. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.